Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides

Receptor-mediated delivery of an antisense oligonucleotide (ASO) using the ligand-conjugated antisense technology is establishing a new benchmark for antisense therapeutics. The triantennary N-acetylgalactosamine (GalNAc(3)) cluster is the first conjugated ligand to yield a marked increase in ASO po...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Brenda F., Xia, Shuting, Partridge, Wesley, Kwoh, T. Jesse, Tsimikas, Sotirios, Bhanot, Sanjay, Geary, Richard S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623620/
https://www.ncbi.nlm.nih.gov/pubmed/36454263
http://dx.doi.org/10.1089/nat.2022.0044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623620/
https://www.ncbi.nlm.nih.gov/pubmed/36454263
http://dx.doi.org/10.1089/nat.2022.0044

Ejemplares similares